Evercore ISI Group Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Maneka Mirchandaney maintains an 'Outperform' rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and raises the price target from $41 to $48.
September 11, 2023 | 1:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group maintains an 'Outperform' rating on Crinetics Pharmaceuticals and raises the price target from $41 to $48.
The news is directly related to Crinetics Pharmaceuticals. The 'Outperform' rating and raised price target by Evercore ISI Group indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100